<DOC>
	<DOC>NCT02829151</DOC>
	<brief_summary>- Prospective, randomized, controlled, multi-center study - A total of 390 subjects with critical limb ischemia will be included according to inclusion and exclusion criteria. - Patients will be randomized in a 1:1:1 manner into triple antiplatelet therapy (TAP: aspirin, clopidogrel, cilostazol) group, dual antiplatelet therapy (DAP: aspirin, clopidogrel) A group, or DAP (aspirin, cilostazol) B group. - All patients will be treated with angioplasty for critical limb ischemia. - Patients will be followed clinically for 1 year after the procedure. - Ankle-brachial index and Image study follow-up (Duplex US or CT angiography) will be performed at 1 year.</brief_summary>
	<brief_title>Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study)</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Patients â‰¥ 19 years old Patients with critical limb ischemia (Rutherford 4 &amp; 5) Successful belowthe knee endovascular intervention. Major bleeding event within recent 3 months or high risk of major bleeding Patients requiring anticoagulation Allergic reactions to antiplatelet drugs Acute limb ischemia Severe hepatic dysfunction (3 times normal reference values) Pregnant women or women with potential childbearing Life expectancy &lt; 1 year due to comorbidity Previous amputations in the target limb</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Peripheral artery disease</keyword>
	<keyword>Critical limb ischemia</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Antiplatelet therapy</keyword>
</DOC>